The role of beta-blockers in the management of chronic obstructive pulmonary disease

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
   PubMed Web of Science ®Google Scholar
• Boudestein LC, Rutten FH, Cramer MJ, et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11(12):1182–1188.
   PubMed Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respi Med. 2015;3(8):631–639.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–139.
   PubMed Web of Science ®Google Scholar
• Lipworth B, Wedzicha J, Devereux G, et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016;48(3):880–888.
   PubMed Web of Science ®Google Scholar
• Lipworth B, Skinner D, Devereux G, et al. Underuse of beta-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909–1914.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rinaldi B, et al. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs. 2017;77(7):721–732.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet (London, England). 2007;370(9589):797–799.
   PubMed Web of Science ®Google Scholar
• Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091–1099.
   PubMed Web of Science ®Google Scholar
• Konecny T, Somers K, Orban M, et al. Interactions between COPD and outcomes after percutaneous coronary intervention. Chest. 2010;138(3):621–627.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol. 2010;106(3):305–309.
   PubMed Web of Science ®Google Scholar
• Enriquez JR, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest. 2011;140(3):604–610.
   PubMed Web of Science ®Google Scholar
• Writing Committee M, Yancy CW, Jessup M, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–e327.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–2394.
   PubMed Web of Science ®Google Scholar
• Dondo TB, Hall M, West RM, et al. Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69(22):2710–2720.
   PubMed Web of Science ®Google Scholar
• Egred M, Shaw S, Mohammad B, et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM: Mon J Assoc Phys. 2005;98(7):493–497.
   PubMed Web of Science ®Google Scholar
• Puente-Maestu L, Calle M, Ortega-Gonzalez A, et al. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med. 2014;108(5):737–744.
   PubMed Web of Science ®Google Scholar
• Schnabel P, Maack C, Mies F, et al. Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. J Cardiovasc Pharmacol. 2000;36(4):466–471.
   PubMed Web of Science ®Google Scholar
• Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144(3):317–322.
   PubMed Web of Science ®Google Scholar
• Bundkirchen A, Brixius K, Bolck B, et al. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003;460(1):19–26.
   PubMed Web of Science ®Google Scholar
• Baker JG, Wilcox RG. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. 2017;72(3):271–276.
   PubMed Web of Science ®Google Scholar
• Tattersfield AE, Cragg DJ, Bacon RJ. Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man. Br J Clin Pharmacol. 1984;18(3):343–347.
   PubMed Web of Science ®Google Scholar
• Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–1667.
   PubMed Web of Science ®Google Scholar
• Wilcox RG, Rowley JM, Hampton JR, et al. Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet. 1980;316(8198):765–769.
   Google Scholar
• Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther. 2010;23(1):1–8.
   PubMed Web of Science ®Google Scholar
• Loth DW, Brusselle GG, Lahousse L, et al. β-adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study. Br J Clin Pharmacol. 2014;77(1):190–200.
   PubMed Web of Science ®Google Scholar
• Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780–1787.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11(7):684–690.
   PubMed Web of Science ®Google Scholar
• Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.
   PubMed Web of Science ®Google Scholar
• Oda N, Miyahara N, Ichikawa H. Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1119–1124.
   PubMed Web of Science ®Google Scholar
• Duffy S, Marron R, Voelker H, et al. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res. 2017;18(1):124.
   PubMedGoogle Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:Cd003566.
   Google Scholar
• Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011;57(21):2127–2138.
   PubMed Web of Science ®Google Scholar
• Ni Y, Shi G, Wan H. Use of cardioselective ß-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40(6):2051–2065.
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250–258.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2015;21(3):278–283.
   PubMed Web of Science ®Google Scholar
• Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224–1238.
   PubMed Web of Science ®Google Scholar
• Wright SP, Verouhis D, Gamble G, et al. Factors influencing the length of hospital stay of patients with heart failure. Eur J Heart Fail. 2003;5(2):201–209.
   PubMed Web of Science ®Google Scholar
• Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42(7):1226–1233.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–887.
   PubMed Web of Science ®Google Scholar
• Farland MZ, Peters CJ, Williams JD, et al. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013;47(5):651–656.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8–14.
   PubMed Web of Science ®Google Scholar
• Du Q, Sun Y, Ding N, et al. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048.
   PubMed Web of Science ®Google Scholar
• Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–920.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241–249.
   PubMed Web of Science ®Google Scholar
• Neef PA, Burrell LM, McDonald CF, et al. Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease. Intern Med J. 2017;47(9):1043–1050.
   PubMed Web of Science ®Google Scholar
• Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A. 2004;101(14):4948–4953.
   PubMed Web of Science ®Google Scholar
• Lin R, Peng H, Nguyen LP, et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of ‘beta-blockers’ in a murine asthma model. Pulm Pharmacol Ther. 2008;21(1):115–124.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Schefold JC, Jankowska E, et al. Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. PLoS One. 2009;4(7):e6411.
   PubMed Web of Science ®Google Scholar
• De Blois J, Simard S, Atar D, et al. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16(3):225–229.
   PubMed Web of Science ®Google Scholar
• Quint JK, Herrett E, Bhaskaran K, et al. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.
   PubMed Web of Science ®Google Scholar
• van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178(7):695–700.
   PubMed Web of Science ®Google Scholar
• Liao K-M, Lin T-Y, Huang YB, et al. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis. 2017;12:2573–2581.
   PubMed Web of Science ®Google Scholar
• Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715–720.
   PubMed Web of Science ®Google Scholar
• Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37(7):1950–1956.
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12(48).
   PubMedGoogle Scholar
• British Thoracic Society. British guideline on the management of asthma. [cited 2017 Sep 20]. Available from: https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. [cited 2017 Sep 21]. Available from: http://ginasthma.org/ 192017-gina-report-global-strategy-for-asthma-management-and-prevention
   Google Scholar
• Hanania NA, Celli BR, Donohue JF, et al. Bronchodilator reversibility in COPD. Chest. 2011;140(4):1055–1063.
   PubMed Web of Science ®Google Scholar
• Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax. 2015;70(7):683–691.
   PubMed Web of Science ®Google Scholar
• Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48(3):664–673.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, van den Berge M, Boucher RC, et al. American Thoracic Society/National Heart, Lung, And Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report. Am J Respir Crit Care Med. 2017;196(3):375–381.
   PubMed Web of Science ®Google Scholar
• Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute beta-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(4):779–786.
   PubMed Web of Science ®Google Scholar
• Morales DR, Dreischulte T, Lipworth BJ, et al. Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. Br J Clin Pharmacol. 2016;82(3):814–822.
   PubMed Web of Science ®Google Scholar
• Morales DR, Lipworth BJ, Donnan PT, et al. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017;15(1):18.
   PubMedGoogle Scholar
• Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21(1):134–141.
   PubMed Web of Science ®Google Scholar
• Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217–227.
   PubMed Web of Science ®Google Scholar
• Grau M, Barr RG, Lima JA, et al. Percent emphysema and right ventricular structure and function: the multi-ethnic study of atherosclerosis-lung and multi-ethnic study of atherosclerosis-right ventricle studies. Chest. 2013;144(1):136–144.
   PubMed Web of Science ®Google Scholar
• Visca D, Aiello M, Chetta A. Cardiovascular function in pulmonary emphysema. Biomed Res Int. 2013;2013:184678.
   PubMedGoogle Scholar
• Casaburi R, Maltais F, Porszasz J, et al. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(9):1351–1361.
   PubMedGoogle Scholar
• Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109(7):785–802.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Di Marco S, et al. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015;10:1917–1923.
   PubMed Web of Science ®Google Scholar
• Stone IS, Barnes NC, James WY, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med. 2016;193(7):717–726.
   PubMed Web of Science ®Google Scholar
• Yang CT, Lin HC, Lin MC, et al. Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease. Eur J Clin Pharmacol. 1996;49(5):341–345.
   PubMed Web of Science ®Google Scholar
• Fisher AA, Davis MW, McGill DA. Acute myocardial infarction associated with albuterol. Ann Pharmacother. 2004;38(12):2045–2049.
   PubMed Web of Science ®Google Scholar
• Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City heart study. Eur Respir J. 2003;21(6):1012–1016.
   PubMed Web of Science ®Google Scholar
• McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J. 2012;39(5):1097–1103.
   PubMed Web of Science ®Google Scholar
• Newnham DM, Wheeldon NM, Lipworth BJ, et al. Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax. 1993;48(6):656–658.
   PubMed Web of Science ®Google Scholar
• Noveanu M, Breidthardt T, Reichlin T, et al. Effect of oral beta-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Critical Care. 2010;14(6):R198.
   PubMed Web of Science ®Google Scholar
• Fuchs C, Wauschkuhn S, Scheer C, et al. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. BJA: Br J Anaesth. 2017;119:616-625.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Connett JE, Voelker H, et al. β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. BMJ Open. 2016;6(6):e012292.
   PubMed Web of Science ®Google Scholar
• Baker JG, Gardiner SM, Woolard J, et al. Novel selective β(1)-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. Faseb J. 2017;31(7):3150–3166.
   PubMed Web of Science ®Google Scholar